SCHOTT Pharma: A GLP-1 Boom Priced by the Dose, Not the Drug, and a Capacity Bill That Has Yet to Prove Its Return

The July agreement is encouraging, but its importance cuts both ways. It supports the view that the weak guide reflected contract timing and customer planning rather than a collapse in end demand. It also shows how one customer’s revised production plan can move group guidance, capacity utilization and market expectations. In the first half of fiscal 2026, one customer generated EUR 50.5 million, approximately 10.3% of group revenue.

The long-term growth case rests on High-Value Solutions. SCHOTT Pharma defines HVS as sterile ready-to-use containers and delivery systems, or products offering additional benefits through coatings, improved break resistance, reduced drug-container interaction or other specialized features. The category includes all DDS revenue and part of DCS revenue. Its share of group revenue rose from 33% in fiscal 2021 to 57% in fiscal 2025. Management says HVS can command prices five to fifteen times those of standard products and produce margins roughly ten percentage points above the company average. Those are management claims, but reported DCS results provide partial corroboration: as the segment’s HVS share increased, its EBITDA margin rose from 19.5% in fiscal 2024 to 23.3% in fiscal 2025 and 25.1% in the first half of fiscal 2026.

The evidence is less clean in DDS. The whole segment qualifies as HVS, yet its margin fell sharply when polymer utilization weakened, product mix shifted and new glass-syringe capacity ramped. High-value classification improves the unit economics of a product, but does not eliminate manufacturing operating leverage. HVS mix is a useful indicator; it is not a substitute for volume, utilization and return on capital.

SCHOTT Pharma has genuine switching costs. Packaging components and suppliers can be specified in regulatory submissions and Drug Master Files, and post-approval changes to a container-closure system may require compatibility, stability, extractables, leachables, sterility and regulatory work. FDA guidance explicitly provides for packaging and container-closure information, including component suppliers and specifications, in Type III Drug Master Files.

Those switching costs accrue most strongly after a supplier has been selected and qualified. Before qualification, pharmaceutical companies can negotiate among SCHOTT Pharma, Stevanato, Gerresheimer and other suppliers, and large customers have strong incentives to qualify more than one source. SCHOTT Pharma does not disclose which GLP-1 programs are sole-sourced, which are dual-sourced, its revenue from GLP-1 drugs, or the specific customers and molecules involved. Regulatory lock-in therefore supports retention and long-lived revenue, but the evidence is insufficient to conclude that it creates unconstrained pricing power.

Capital intensity is the central economic test. SCHOTT Pharma generated EUR 986.2 million of revenue in fiscal 2025 and invested EUR 143.1 million through ongoing investing cash flow. Fiscal 2026 capital expenditure is expected to be EUR 140–160 million, excluding leases. The spending supports glass-syringe and cartridge capacity in Hungary, sterile cartridges in Switzerland, specialty vials and polymer syringes in Germany, prefillable syringes in India, ampoules in Serbia and sterile-vial expansion in the United States.

The company discloses evidence of customer commitment. At September 2025 it had approximately EUR 1.14 billion of unsatisfied performance obligations from contracts extending to 2035, while EUR 143 million of contract liabilities largely represented advance payments from three customers for long-term series supply. The disclosure does not show how much new capacity is fully pre-contracted, whether contracts contain take-or-pay provisions, how prices escalate, or what returns individual projects are expected to earn.

Governance deserves a valuation discount rather than a footnote. SCHOTT AG indirectly controls 77% of the shares and is wholly owned by the Carl Zeiss Foundation. SCHOTT Pharma Management AG is the general partner that manages the KGaA, and the general partner is itself owned by the SCHOTT group. Public shareholders cannot replace management through the ordinary mechanisms available in a conventional German AG. The broader group also supplies glass tubing and corporate services; fiscal 2025 purchases and services from SCHOTT-related entities were approximately EUR 188.9 million.

The controlling structure can encourage patient investment and protect the company from short-term financial engineering. It simultaneously limits takeover optionality, minority influence and the market discipline that comes with contestable control. Although shares outside the 77% block amount to about 23%, Deutsche Börse’s current index methodology treats additional large holdings as strategic and assigns an effective free float of approximately 18%. That constrains liquidity and the weight available to index investors.

The market originally traded SCHOTT Pharma as a clean GLP-1 and biologics compounder. The IPO was priced at EUR 27 on September 28, 2023, the first quotation was EUR 30, and the shares reached EUR 43.40 in February 2024. They subsequently fell as the market confronted slower packaging growth, polymer normalization, rising capital expenditure and customer-specific syringe uncertainty, reaching EUR 12.60 in March 2026 before recovering to EUR 22.15 following better results and the July guidance increase.

At EUR 22.15, the shares trade at approximately 23.1 times consensus fiscal 2026 earnings and 12.3 times enterprise value to consensus EBITDA. Consensus free cash flow of roughly EUR 64.5 million implies a yield below 2% on the current market capitalization. The earnings multiple is far below West and only modestly below Stevanato, while the EBITDA multiple is far below both, but the free-cash-flow yield reflects the capital required to turn the secular opportunity into qualified capacity.

The qualitative portrait is a company in transition: a technically credible, sticky supplier moving toward better formats while carrying the utilization, capital-spending and governance burdens of an industrial manufacturer. Whether it becomes a high-quality compounder turns on converting current capacity spending into sustained 6–8% organic growth, margin recovery toward 30% and materially stronger free cash flow. The evidence presently supports that possibility, but not yet the completed transformation.

Vertical history and financial evolution

SCHOTT Pharma’s industrial lineage is much older than its listed history. Otto Schott’s development of borosilicate glass in 1887 created a material resistant to heat and chemical attack. SCHOTT introduced FIOLAX pharmaceutical tubing in 1911 and began manufacturing ampoules in 1923. The early problem was how to produce a chemically stable, dimensionally consistent container capable of preserving injectable medicines through filling, storage, transport and administration, not simply how to form a glass bottle.

The business expanded alongside the globalization of pharmaceutical manufacturing. Production was established in Brazil in 1954, Spain in 1963, France in 1968, the United States in 1992, Italy in 1994, Hungary in 1996, India in 1997 and several additional markets thereafter. That footprint matters because pharmaceutical customers prefer validated supply close to filling operations, while regulators and procurement departments value redundancy across regions. By 2025 the business operated in fourteen countries and produced more than 13 billion units annually.

The first broad stage was therefore an industrial-materials and global-footprint phase. The capability built during this period was process consistency at very high volume: converting glass tubing into containers with narrow tolerances, controlling cosmetic and functional defects, and supporting pharmaceutical qualification. Standard ampoules and bulk vials provided scale; higher-specification syringes, cartridges, coated containers and ready-to-use formats gradually provided differentiation.

A second stage emerged around biologics, sterile fill-finish and the pandemic. Biologic molecules are more sensitive to interaction with glass, silicone, elastomers and tungsten residues than many traditional small molecules. Customers increasingly wanted washed, sterilized and ready-to-fill components that removed process steps from their plants or contract manufacturers. The pandemic then drove extraordinary demand for vaccine vials and polymer syringes suitable for deep-cold or demanding storage conditions. SCHOTT Pharma’s HVS revenue share rose from 33% in fiscal 2021 to 48% by fiscal 2023.

The pandemic acceleration made a separate listing plausible. SCHOTT Pharma was legally carved out as a standalone KGaA in 2022, although the industrial operations and commercial relationships came from the longstanding SCHOTT pharmaceutical-packaging division. The separation created carve-out financial statements but did not sever economic links with the parent. SCHOTT continued to supply glass tubing and shared services, and retained control through the general partner and a 77% shareholding.

The IPO on September 28, 2023 was a secondary placement of existing shares rather than a primary capital raise for SCHOTT Pharma. Approximately 34.6 million shares were sold at EUR 27, producing a transaction volume of roughly EUR 935 million and an initial public free float near 23%. The proceeds went to the selling SCHOTT group rather than into SCHOTT Pharma’s operating balance sheet. At the issue price, the equity value was approximately EUR 4.07 billion; the first trade at EUR 30 implied approximately EUR 4.52 billion.

The IPO story combined defensive pharmaceutical demand, a migration toward ready-to-use and high-value formats, double-digit market growth assumptions for the relevant premium categories, and GLP-1 and mRNA exposure. Management at the time targeted more than 10% medium-term revenue growth and an EBITDA margin in the low thirties. SCHOTT Pharma entered the SDAX in December 2023.

The third stage, from the IPO through fiscal 2025, was an investment and expectation-reset phase. Revenue and EBITDA continued to rise, and HVS mix reached 57%. Yet the composition changed. Standard products were slower, polymer vaccine demand normalized, and the company committed capital to sterile cartridges, glass syringes and high-value vials before all of that capacity contributed revenue. The market moved from pricing a clean secular-growth story to scrutinizing the lag between investment, customer qualification and commercial utilization.

The fourth stage began with fiscal 2026. Management originally described the year as a bridge period, guiding to only 2–5% constant-currency revenue growth and an EBITDA margin around 27%. The guide incorporated weaker polymer demand and a revised production outlook from a major glass-syringe customer. The July 2026 customer agreement and raised guide improved the near-term picture, but the episode exposed the operating sensitivity hidden beneath a diversified customer count.

The financial record since fiscal 2021 shows a business that has grown faster than its end market while reinvesting most of the resulting cash.

Source: SCHOTT Pharma annual-report series. Constant-currency growth uses the company’s October-to-September fiscal periods and should not be compared without adjustment to calendar-year peers.

Revenue expanded at an approximately 11% compound rate from fiscal 2021 to fiscal 2025, while EBITDA grew about 14% annually. The margin improvement came mainly from HVS mix, price and manufacturing efficiency rather than financial leverage or acquisition accounting.

Earnings quality before capital expenditure is sound. Aggregate operating cash flow over fiscal 2021–2025 was about 1.33 times aggregate net income. Individual annual conversion ranged from roughly 1.2 to 1.5 times. Working-capital movements cause volatility, but there is no persistent pattern of accounting profit exceeding operating cash generation.

Free cash flow tells a less comfortable story. Ongoing investing consumed between EUR 96 million and EUR 171 million annually during the period. Free cash flow averaged only about EUR 41 million, and fiscal 2023 produced EUR 10 million despite EUR 152 million of net income. The company is funding a capacity cycle whose economic return is not yet proven; it is not financially distressed.

ROCE fell from 24.5% in fiscal 2021 to 18.7% in fiscal 2025. Part of this is mechanical: assets under construction enter the capital base before they generate fully qualified output. A recovery in ROCE would confirm that Hungary, Switzerland, India, Serbia and the US expansion are filling as intended. A further decline after those sites reach commercial production would imply that the company overpaid for growth or accepted weaker contracts.

The balance sheet remains manageable. Net debt was EUR 122.2 million at September 2025 and approximately EUR 110 million at March 2026, less than half one year’s EBITDA. The equity ratio at March 2026 was 58.6%. The larger concern is structural dependence on the SCHOTT group. At the half year SCHOTT Pharma reported EUR 165.8 million of financial receivables from group entities and EUR 224.1 million of group financial liabilities, in addition to lease liabilities of EUR 81.7 million.

Fiscal 2025 revenue reached EUR 986.2 million, up 5.8% at constant currency, while EBITDA increased to EUR 280.3 million and the margin rose to 28.4%. Net income fell to EUR 147 million because of higher interest and a normalized tax rate. Gross margin was stable at 33.7%; improvement in DCS offset polymer underutilization in DDS. R&D expenditure was EUR 27.9 million, or 2.8% of sales, consistent with an advanced industrial supplier rather than a research-intensive biotechnology company.

The first half of fiscal 2026 produced EUR 488.1 million of revenue, 1.0% reported growth and 2.3% constant-currency growth. EBITDA was EUR 129.8 million, down 0.6%, with the margin at 26.6%. Net income declined 5.4% to EUR 64.4 million. Operating cash flow improved to EUR 95.1 million, and free cash flow more than doubled to EUR 45.4 million, helped by receivables management.

Gross margin fell from 33.3% to 31.7%. The causes were lower polymer utilization and a high-single-digit-million-euro inventory impairment related to glass syringes. Management said that, excluding the impairment, DDS profitability would have been close to the prior-year level. That adjustment is useful for measuring underlying operations. But the inventory loss is economically real, and it illustrates the forecasting risk in producing specialized containers ahead of final customer requirements.

The quarterly sequence improved and then weakened before the preliminary third-quarter rebound. Fiscal Q1 revenue increased 4.8% at constant currency and the EBITDA margin rose to 27.1%. Fiscal Q2 revenue was approximately flat at constant currency, while its margin fell to 26.0% from 28.5%, reflecting the inventory impairment and DDS pressure. Preliminary fiscal Q3 revenue growth accelerated to about 8% at constant currency and the margin returned to approximately 27%.

Share-price history is short but informative. Investors initially paid EUR 27 at the IPO and quickly pushed the shares above EUR 30. The GLP-1 and HVS narrative supported a high of EUR 43.40 on February 29, 2024. The subsequent fall to EUR 12.60 on March 23, 2026 reflected both earnings revisions and multiple compression: investors ceased treating all injectable-drug growth as directly transferable to packaging volumes and began discounting polymer underutilization, capex and customer timing.

The recovery to EUR 22.15 by August 5, 2026 followed improving DCS economics, stronger cash flow, preliminary third-quarter acceleration and the raised guide. The current price remains 18% below the IPO price and about 49% below the listed high. Price declines alone do not establish undervaluation. Fiscal 2026 consensus EPS of EUR 0.96 is slightly below fiscal 2025 EPS of EUR 0.97, so the present valuation still assumes that the bridge year is followed by renewed growth.

Business model, moat, governance and industry cycle

SCHOTT Pharma reports two segments. Drug Containment Solutions supplies vials, ampoules and cartridges. Drug Delivery Systems supplies prefillable glass and polymer syringes. DCS has more standard products and currently lower margins, but its HVS migration provides the clearest mix-expansion opportunity. DDS is entirely classified as HVS and historically had the higher margin, but its fixed-cost structure makes it sensitive to polymer and glass-syringe utilization.

Source: fiscal 2025 annual report and fiscal 2026 half-year disclosure.

DDS generated 44.5% of fiscal 2025 revenue but 54.5% of segment EBITDA. DCS generated 55.5% of revenue and is becoming more profitable as ready-to-use cartridges, ready-to-use vials and specialty vials increase. During the first half of fiscal 2026, DCS’s margin expansion almost offset the DDS decline at group level.

The exact glass-versus-polymer split is not disclosed. Investors know that prefillable glass-syringe demand is strong and polymer demand is weak, but cannot calculate polymer revenue, product-level gross margin, capacity utilization or the earnings contribution that remains at risk. This is one of the report’s largest information gaps.

HVS is an economically useful but broad management category. It encompasses sterile ready-to-use products and products offering special technical benefits, including coated vials and cartridges, sterile cartridges, specialty vials, and prefillable glass and polymer syringes. The definition has been broadly stable since the IPO. It mixes products with different utilization and margin profiles, which is why HVS share must be read together with segment margin and cash return.

A standard bulk vial is primarily a converting product: glass tubing is formed, inspected and shipped to a customer that performs washing, sterilization and filling. A ready-to-use vial or cartridge adds washing, depyrogenation, sterilization, validated packaging and quality documentation. The supplier performs more of the customer’s process and assumes more compliance responsibility, supporting higher prices and margins.

The customer benefit is substantial even if the packaging price remains small compared with the medicine’s value. Ready-to-use systems can shorten fill-finish preparation, reduce contamination risk, simplify validation and permit flexible small-batch manufacturing. This is especially relevant for biologics, clinical-stage products and contract manufacturers that fill multiple drugs on one line.

The cost base contains significant fixed elements. Glass forming equipment, cleanrooms, sterile processing, furnaces, inspection systems, quality laboratories, depreciation and trained labor remain in place across fluctuations in output. Glass tubing, energy, packaging materials and logistics are more variable, but cannot fully offset a volume decline. DDS’s first-half performance illustrates the operating leverage: a relatively modest revenue decline produced an 18% EBITDA decline.

Growth also requires long lead times. A company must select a site, order specialized machinery, install cleanroom and inspection capacity, validate the manufacturing process, provide stability samples, support customer qualification and receive regulatory acceptance before meaningful commercial revenue begins. The lag can run for years. The Hungary glass-syringe and cartridge facility moved through inauguration, final qualification and initial production during fiscal 2025–2026, while commercial sterile-cartridge supply began in Switzerland.

The Hungary ramp is therefore both a cost and a leading indicator. Its early output contributed to glass-syringe growth in the first half of fiscal 2026, while ramp expenses and incomplete utilization weighed on DDS margin. The company has not disclosed unit capacity, customer allocation, contracted utilization, project cost or expected project ROCE. The July key-customer agreement improves the probability of filling the site, but cannot substitute for those missing numbers.

Contract disclosure is stronger than at many industrial suppliers but incomplete. The EUR 1.14 billion of remaining obligations through 2035 and EUR 143 million of customer advances show that some capacity is backed by long-duration commitments. The company’s 97% repeat-revenue rate and customer relationships averaging more than ten years support stickiness. The top five customers contribute roughly 30% of revenue and customers ranked six through ten contribute approximately another 15%.

The disclosure does not identify minimum purchase quantities, termination rights, raw-material pass-through clauses, inflation escalators or penalties for customer forecast changes. “Long-term contract” should not be read automatically as take-or-pay. The first-half customer revision shows that schedules can still move even when the commercial relationship survives.

The strongest moat is regulated process qualification combined with manufacturing consistency, not the SCHOTT name alone. Once a container, coating, silicone process and supplier have been incorporated into a drug’s technical file, switching can require stability work, compatibility testing, documentation and regulatory submissions. The consequences of a defective container can include contamination, breakage, particles, loss of sterility, drug aggregation or a product recall.

The second moat is scale across product formats and geographies. SCHOTT Pharma serves more than 1,800 customers, produces over 13 billion units annually and operates a manufacturing network spanning Europe, the Americas and Asia. Customers can source a standard vial, high-performance vial, cartridge, ampoule or syringe from one supplier and qualify production in several regions.

The third is accumulated process knowledge. Dimensional tolerances, glass chemistry, coating behavior, sterilization, siliconization and cosmetic-defect control are learned through large production datasets and customer failure analysis. Patents help at the edge, but the more durable advantage is the ability to reproduce validated output at commercial scale.

Pricing power is narrower than the moat narrative sometimes implies. Large pharmaceutical companies understand that qualification creates dependency and commonly mitigate it through dual sourcing. Competition is strongest before a product is written into a filing or before a new manufacturing site is approved. A supplier can earn attractive margins after qualification while still conceding price and contract protection during the initial award.

The company’s HVS price and margin claims indicate differentiation, but the reported record suggests that pricing power is format-specific. DCS’s HVS migration produced clear margin expansion. DDS could not prevent a five-percentage-point margin decline when polymer volumes and glass mix weakened. The moat protects the relationship more reliably than it protects factory utilization.

Customer concentration is moderate at group level and potentially high at product-program level. More than 1,800 customers sound diversified, but one major GLP-1 syringe program can occupy a meaningful share of a particular line. The key-customer event during fiscal 2026 confirms that program concentration can matter before it becomes visible in the group’s annual customer table.

The company does not disclose GLP-1 revenue, customer names, molecules, unit commitments or sourcing status. Management has referred to long-term contracts with major GLP-1 participants, and glass-syringe demand is explicitly linked to those therapies. Any precise percentage assigned to GLP-1 exposure would be speculative.

Oral GLP-1 products are now a concrete substitution variable. An oral version of Wegovy received European approval in July 2026, while Lilly has completed successful late-stage studies of the oral small-molecule orforglipron. Oral products can broaden the market while reducing the proportion of doses requiring syringes or cartridges. Injectables may retain advantages in efficacy, dosing frequency and patient preference, so the likely downside is a lower injectable share of a growing market rather than the disappearance of obesity demand.

Device architecture is another variable. Some therapies are sold in prefilled syringes, some in cartridges inserted into reusable or disposable pens, and others in autoinjectors whose primary container may be sourced separately from the assembled device. SCHOTT Pharma participates in syringes and cartridges but lacks Stevanato’s comparable position in integrated pen injectors and West’s position in elastomeric closures. Growth in the drug category can therefore be captured differently depending on the selected device.

The industry is defensive at the level of treatment demand but cyclical at the level of customer inventory and supplier capacity. Pharmaceutical products continue to be consumed through recessions, while customers can build or reduce packaging inventory, postpone qualification, change launch timing and revise capacity reservations. Pandemic demand created a particularly large inventory and capacity cycle in polymer syringes and vaccine packaging.

The supply chain also contains raw-material and energy exposure. SCHOTT Pharma buys glass tubing from the wider SCHOTT group under long-term arrangements. This provides technological alignment and supply continuity, but places an important input and its transfer economics inside a related-party relationship. Fiscal 2025 purchases and services from SCHOTT-related parties were almost EUR 189 million, equal to roughly 19% of group revenue.

Governance compounds that dependence. SCHOTT Glaswerke Beteiligungs- und Export GmbH holds 77%, is controlled by SCHOTT AG, and ultimately belongs to the Carl Zeiss Foundation. SCHOTT Pharma Management AG, the personally liable general partner, is also owned by the same group. Its management board runs the listed partnership.

The KGaA structure means public shareholders vote on some supervisory and capital matters but cannot remove the general partner through an ordinary shareholder vote. Two supervisory boards operate within the structure, with limited overlap intended to facilitate information exchange. If the SCHOTT group’s holding fell below 30%, the articles provide for automatic conversion into an AG, but there is no public indication that such a reduction is planned.

The governance discount arises from three cumulative constraints: controlled ownership, a controller-owned general partner and material related-party dependence. A hostile takeover is practically unavailable, activist influence is limited, and minority shareholders rely on the controller’s willingness to allocate capital fairly. Clean audit opinions and a dependency report finding adequate consideration reduce concerns about current misconduct, but they do not restore contestable control.

Christian Mias became CEO on May 1, 2026, succeeding Andreas Reisse upon his planned retirement. Mias has more than twenty years of management experience, including over eighteen years in SCHOTT businesses and earlier responsibility for SCHOTT Tubing, international manufacturing and restructuring work. Reinhard Mayer has served as CFO since August 2025.

The succession favors continuity rather than outside challenge. That can be valuable during a technically complex capacity ramp. It also means investors have limited evidence that the new leadership will question parent-company arrangements, cancel low-return projects or provide more product-level disclosure. Management credibility over the next two years will depend less on narrative and more on ROCE, DDS utilization and free-cash-flow delivery.

Horizontal competitors and current fundamentals

SCHOTT Pharma competes in a concentrated but segmented field. Stevanato Group is the closest listed pure-play comparison. Gerresheimer overlaps in glass and plastic pharmaceutical packaging but has a broader, more leveraged portfolio. AptarGroup is less direct in glass, yet its Pharma division competes in drug-delivery components and injectables. West Pharmaceutical Services supplies elastomer closures, seals and delivery components that sit next to SCHOTT containers in the same regulated system.

† US-listed market capitalizations translated at EUR 1 = USD 1.1554, the ECB reference rate for August 5, 2026. ‡ SCHOTT figure is preliminary fiscal Q3 constant-currency growth; complete nine-month accounts were not yet published. Valuation multiples use different reporting bases and are directional rather than perfectly comparable.

Stevanato became the premium pure-play for sterile ready-to-use containment. Its EZ-fill portfolio, high-performance syringes, cartridges, engineering systems and growing device capabilities create a more vertically integrated customer proposition than SCHOTT Pharma’s. The Engineering segment can supply inspection, assembly and manufacturing equipment alongside the containers, helping customers industrialize new formats.

In the second quarter of 2026, Stevanato revenue increased 8% to EUR 302 million and adjusted EBITDA increased 21% to EUR 78.7 million, producing a 26.0% margin. HVS revenue in its Biopharmaceutical and Diagnostic Solutions segment rose 16% and represented 51% of segment revenue. Its plants in Fishers, Indiana, and Latina, Italy, are also ramping, showing that qualification delays and under-absorption are industry issues rather than unique to SCHOTT Pharma.

Customers pick Stevanato when they value ready-to-use breadth, integrated engineering and device development. Investors pay a large premium for that combination: the shares trade around the mid-twenties on forward earnings and above twenty times trailing EBITDA. The premium presumes continued HVS growth and successful absorption of its new plants.

SCHOTT Pharma has comparable current EBITDA margins and a longer glass heritage, but less transparent device integration and weaker near-term growth. It deserves some discount. A valuation gap approaching one full turn of earnings quality, however, would narrow if SCHOTT delivers 6–8% growth and DCS margin expansion without a further capex increase.

Gerresheimer became a broad pharmaceutical- and consumer-packaging consolidator. Its portfolio includes molded glass, tubular glass, plastics, drug-delivery systems and consumer packaging. The acquisition of Bormioli Pharma increased pharmaceutical scale but added leverage and integration demands. The company subsequently suffered repeated guidance cuts, project delays, production-ramp costs, weak non-pharma demand and regulatory scrutiny concerning accounting.

Gerresheimer’s June 2026 outlook called for only a 17–18% adjusted EBITDA margin and negative free cash flow of EUR 50–100 million. Its share price of EUR 26.36 on August 5 implied a market capitalization below EUR 1 billion. That is a dramatic discount to its EUR 2.3 billion fiscal 2025 revenue.

The comparison is instructive. Gerresheimer shows how capacity expansion, acquisitions, leverage and weak execution can overwhelm a favorable injectable-drug narrative. It is cheaper than SCHOTT Pharma because its balance sheet, accounting credibility and operational control are weaker. SCHOTT should not be valued down to Gerresheimer merely because both make glass packaging. Gerresheimer nevertheless provides the clearest warning of what happens when capital commitments outrun qualified demand.

AptarGroup became a diversified dispensing and drug-delivery company. Beauty and Closures reduce its purity as an injectable-drug comparison, while Aptar Pharma supplies nasal, pulmonary, ophthalmic, injectable and consumer-healthcare delivery systems. Its differentiation sits more in delivery mechanisms, valves, pumps and formulation-device interaction than in converting glass tubing.

Second-quarter 2026 reported sales exceeded USD 1 billion, up 6%, while core sales grew only 1%. Group adjusted EBITDA margin declined to 20.7%; Pharma’s margin remained much higher at 33.6% despite an 180-basis-point decline. Injectables core sales increased 9%.

Customers choose Aptar for delivery-device engineering and broad drug-administration expertise. Investors accept a lower growth rate because of diversification, recurring pharma exposure, dividends and buybacks. At approximately 11.6 times trailing EBITDA, Aptar’s group multiple is close to SCHOTT Pharma’s forward multiple, but the composition differs: Aptar offers better cash returns and diversification, while SCHOTT offers more concentrated upside from sterile containment.

West became the premium bottleneck supplier in the container-closure ecosystem. Its elastomer stoppers, plungers and seals must maintain sterility and drug compatibility, and a container system may require both a SCHOTT or Stevanato glass component and a West elastomer component. West’s position is therefore partly complementary rather than directly substitutive.

West’s second-quarter 2026 sales increased 13.8%, including 12.7% organic growth. Adjusted operating margin rose to 22.6%, operating cash flow was USD 213.9 million and free cash flow was USD 128 million. GLP-1-related elastomer demand contributed materially to high-value growth.

The market assigns West a much higher multiple, about 27 times trailing EBITDA and around 40 times earnings, because its high-value components, free-cash-flow record and regulatory position have historically been stronger. West’s violent 2025 share-price decline after weak guidance also shows that even the industry’s best franchise is vulnerable when growth assumptions reset.

SCHOTT Pharma’s niche is the diversified containment-and-syringe supplier between Stevanato’s premium integration and Gerresheimer’s broader industrial portfolio. Its current margins are competitive and the balance sheet is healthier than Gerresheimer’s. The valuation sits far below Stevanato and West. Disclosure, cash generation and governance are weaker than at those premium peers.

The latest operating evidence has improved. Fiscal 2025 met company targets; fiscal Q1 2026 began strongly; fiscal Q2 exposed the polymer and inventory problems; preliminary Q3 restored growth and led to a raised guide. The market is now trading the probability that fiscal 2026 is a temporary trough rather than the beginning of a lower-growth regime.

Consensus compiled on July 27, 2026 forecasts fiscal 2026 EBITDA of EUR 279.3 million, a 27.3% margin and EPS of EUR 0.96. Fiscal 2027 estimates rise to EUR 307.5 million of EBITDA and EPS of EUR 1.07, with fiscal 2028 at EUR 335.1 million and EUR 1.18 respectively. Consensus therefore assumes that fiscal 2026 earnings remain close to flat, followed by low-double-digit EPS growth.

The bulls can point to four pieces of evidence. DCS HVS mix is producing reported margin expansion. Glass-syringe demand remains high. Long-term obligations and advance payments provide some capacity backing. The July customer agreement restored enough volume confidence for management to lift both revenue and margin guidance.

The bears also have concrete evidence. DDS revenue and EBITDA declined despite strong GLP-1 demand. Polymer utilization has not recovered. ROCE has fallen during the investment cycle. One customer can move guidance. The current free-cash-flow yield remains below 2% after the share-price recovery.

The most important disagreement concerns the nature of the fiscal 2026 slowdown. A temporary interpretation says pandemic polymer demand is approaching a normalized base, the glass-customer schedule has been resolved, and qualified new capacity will raise revenue and margins from fiscal 2027. A structural interpretation says the company’s attainable packaging growth is closer to 3–5%, customers retain negotiating power through dual sourcing, and repeated investment is required merely to preserve its technical position.

Evidence currently favors a cyclical and customer-timing explanation for most of the near-term slowdown. The raised guide and DCS performance are difficult to reconcile with a broad loss of competitiveness. The structural bear case remains relevant because the company has not quantified the returns, contracted utilization or product-level economics of its capacity program.

Valuation, risks and tracking dashboard

The listed history covers less than three years, so a statistical historical percentile would imply more precision than the data support. The shares are below the EUR 27 IPO price, far below the EUR 43.40 peak and above the EUR 12.60 trough. Fiscal 2026 earnings are close to fiscal 2025 levels. The current multiple is therefore primarily a judgment about the fiscal 2027–2029 recovery rather than a reward for current growth.

At EUR 22.15, equity value is approximately EUR 3.34 billion. Adding EUR 110 million of March 2026 net debt produces enterprise value of approximately EUR 3.45 billion. Against consensus fiscal 2026 EBITDA of EUR 279.3 million and EPS of EUR 0.96, that is 12.3 times EV/EBITDA and 23.1 times earnings.

Consensus fiscal 2026 free cash flow is EUR 64.5 million, equivalent to a 1.9% yield. Fiscal 2027 consensus free cash flow of EUR 77.6 million would increase the yield to only 2.3% at the current market capitalization. The shares are inexpensive relative to West or Stevanato on earnings and EBITDA, but not on cash produced after current investment.

Cash-flow passthrough requires separating maintenance and growth expenditure. The aggregate operating-cash-flow-to-net-income ratio was 1.33 times in fiscal 2021–2025, confirming that working capital and accounting quality are not the main problem. Full capital expenditure is.

SCHOTT Pharma does not disclose maintenance capex. Fiscal 2025 depreciation and amortization was about EUR 79 million, while capex was approximately EUR 147 million. I use EUR 75–90 million as a maintenance range and treat the remaining EUR 55–75 million of the fiscal 2026 guide as growth investment. This assumption is uncertain because sterile-capacity maintenance can exceed accounting depreciation.

On fiscal 2025 actual cash flow, operating cash flow of EUR 179.9 million less EUR 80 million of estimated maintenance capex gives owner earnings near EUR 100 million, implying about 33 times owner earnings. On normalized fiscal 2026 consensus, free cash flow of EUR 64.5 million plus estimated growth capex of roughly EUR 65–75 million gives owner earnings of EUR 130–140 million, implying about 24–26 times owner earnings. The normalized owner-earnings multiple is close enough to the headline P/E to use both measures. But the weak reported free-cash-flow yield warrants giving owner earnings and EV/EBITDA more weight than EPS alone.

SCHOTT Pharma trades at a large discount to Stevanato and West and around Aptar’s group EV/EBITDA. The discount reflects slower current growth, concentrated ownership, KGaA governance, lower free-cash-flow conversion and uncertain DDS utilization. It should narrow if the company reaches 6–8% growth and a margin near 30%; it should persist if growth settles below 5%.

The valuation below uses a blend of normalized owner earnings, EV/EBITDA and a simplified discounted cash-flow check. The values are current intrinsic-value estimates in EUR per share, rather than analyst price targets.

The conservative case assumes DCS remains healthy but DDS fails to reaccelerate, keeping the group near its current margin. The base case assumes polymer headwinds diminish, Hungary and Switzerland fill progressively, HVS exceeds 60%, and margin recovers without another step-up in capex. The optimistic case requires management’s 6–8% midterm growth and near-30% margin targets to be achieved with stronger free-cash-flow conversion. These are research scenarios, not investment advice.

The market’s current expectation is close to the conservative-to-base boundary. Investors no longer price the low-thirties margin and double-digit growth story told at the IPO. They still assume that fiscal 2026 is a pause: a 23 times earnings multiple would be difficult to sustain if EPS remained around EUR 1.00 indefinitely.

The next expectation gap will arise from DDS rather than DCS. A positive surprise would be positive DDS constant-currency growth, a margin returning above 33%, and evidence that Hungary is absorbing fixed costs. A negative surprise would be another customer rescheduling, continued polymer decline or additional inventory provisions.

The most fragile base-case assumption is margin recovery toward 29%. If only 70% of the assumed improvement is realized and revenue growth is simultaneously one to two percentage points lower, normalized owner earnings would be nearer EUR 145–150 million than EUR 165 million. The base value would fall from EUR 26 to approximately EUR 22–23 per share.

The current price is only marginally below the EUR 22.5 conservative estimate, far short of a 20% margin of safety. If EPS and the valuation multiple remain flat for three years, the expected return is approximately the dividend yield, around 0.8–0.9% annually. That is below the 3.13% yield on the ten-year German Bund on August 5, 2026. There is no margin of safety at this buy price.

Margin-of-safety sufficiency verdict: none.

The largest permanent-loss risks are specific rather than macroeconomic.

Customer and program concentration has medium probability and high impact. The observable indicator is a revision to DDS guidance, a top customer above 12% of revenue or another change to committed glass-syringe schedules. The transmission path runs from delayed orders to lower line utilization, inventory charges, margin contraction and a lower growth multiple. The July agreement reduced immediate risk but confirmed the mechanism.

Polymer underutilization has medium-to-high probability and medium-to-high impact. The indicator is continued DDS contraction after the mRNA comparison has annualized, particularly if polymer-related assets are impaired or management announces repurposing. Persistent fixed costs would hold DDS margin below its historical mid-thirties level and indicate that part of pandemic-era capacity has no near-term economic use.

Capacity-return risk has medium probability and high impact. Investors should compare capex, revenue growth and ROCE once Hungary, Switzerland, India and Serbia reach commercial output. Capital expenditure above EUR 160 million while organic growth remains below 5%, or ROCE below 17%, would suggest that new investment is diluting returns.

GLP-1 modality and architecture substitution has medium long-term probability and high impact on the premium narrative. Oral semaglutide is already approved for obesity in Europe, and oral small molecules are progressing. The relevant indicator is injectable share, not total obesity-drug sales. A growing market could still disappoint SCHOTT if oral products take incremental patients or if customers favor cartridges, pens or competitors’ integrated devices.

Governance and related-party risk has high probability of remaining present and medium impact. No misconduct is required for the discount to persist. The indicators are the SCHOTT stake, effective Deutsche Börse free float, terms of tubing and service agreements, cash-pool exposures and any secondary placement. The structure limits takeover value and can prevent a valuation convergence with ordinary listed peers.

Valuation and liquidity risk has medium probability and medium-to-high impact. An effective free float around 18% and moderate trading volume can amplify moves around results. If fiscal 2027 EPS expectations fall below EUR 1.00, a decline from 23 times to 17–18 times earnings would take the share price toward EUR 17–18 even without balance-sheet distress.

Positive catalysts include full nine-month results confirming the preliminary Q3 acceleration; disclosure that the July glass-syringe agreement provides multi-year utilization; DDS margin recovery; successful Hungarian qualification; HVS share above 60%; and fiscal 2027 guidance aligned with 6–8% organic growth.

Negative catalysts include another customer schedule change; a polymer asset impairment; fiscal 2027 growth guidance below 5%; capex above the current range; ROCE deterioration after ramp completion; a controller-related transaction viewed as unfavorable to minorities; or evidence that oral GLP-1 adoption is reducing syringe and cartridge forecasts.

The complete nine-month release on August 12 is the immediate test. Investors should reconcile preliminary growth and margin with segment revenue, working capital, capex and the exact treatment of the customer agreement. A headline confirmation with weak DDS detail would be less constructive than the group figures suggest.

Over the following year, the dashboard should be read as a system. Capex above EUR 150 million is acceptable if DDS and DCS grow and ROCE stabilizes. Margin improvement without cash generation could reflect working-capital timing. Higher HVS share without better DDS utilization would show why the category alone cannot carry the thesis.

Cross-synthesis and final research conclusion

Looking vertically, SCHOTT Pharma has proven one capability over more than a century: it can convert specialized glass and polymers into regulated pharmaceutical components at global scale and maintain customer relationships through multiple technology cycles. The business survived the move from ampoules to vials, from bulk to ready-to-use formats, from small molecules to biologics, and from manual filling to highly automated injection devices. That durability is stronger evidence of quality than the short listed history.

Past growth came from a combination of industry evolution and company capability. The biologics trend increased technical requirements. The pandemic provided an exceptional volume tailwind. Management invested in sterile processing and higher-value formats before demand was fully visible. The increase in HVS share and DCS margin shows that the strategic direction was correct. The polymer decline shows that some of the volume and capacity assumptions were cyclical.

The company’s true advantage is narrower and more durable than the IPO narrative. It can qualify and manufacture drug-containment systems reliably, across regions and at scale. Once selected, it is difficult to replace. It has not proven an ability to capture a fixed share of the economic value generated by GLP-1 or other high-priced drugs, and it remains exposed to the initial procurement power of large pharmaceutical customers.

Horizontally, SCHOTT sits in the middle of the quality spectrum. Gerresheimer carries more leverage, operational complexity and accounting uncertainty. Stevanato offers stronger integrated ready-to-use and device capabilities and is growing faster. West controls an especially sensitive elastomeric part of the container-closure system and converts more of its earnings into cash. Aptar provides greater diversification and shareholder distributions.

SCHOTT’s valuation correctly reflects much of this ranking. It trades at a steep discount to Stevanato and West but does not trade at Gerresheimer’s distressed level. At approximately 12.3 times fiscal 2026 EBITDA, the market is paying for a sound regulated supplier and some recovery, while refusing to capitalize the IPO’s full compounder narrative.

The principal market misjudgment during 2024–2025 was treating drug-value growth and packaging-unit growth as the same variable. The primary-packaging market grows much more slowly than the revenue generated by the drugs it protects. The likely current misjudgment is subtler: the market may underestimate how much the fiscal 2026 slowdown was caused by one customer’s schedule and the polymer unwind, while simultaneously overestimating how automatically new capacity will produce attractive returns.

The next twelve months are about utilization. The critical variables are DDS growth, Hungary’s ramp, polymer comparisons, customer schedules and fiscal 2027 guidance. Strong DCS results alone cannot establish the compounder case because DCS is already carrying the group while DDS absorbs the most visible pressure.

The three-year test is cash conversion. By fiscal 2029, revenue growth should be within management’s 6–8% range, EBITDA margin should be moving toward 30%, HVS share should exceed 60%, and free cash flow should rise materially despite a normalized maintenance burden. If EBITDA grows while free cash flow remains around EUR 50–80 million, the company will have behaved like a capital-intensive component supplier rather than a compounder.

The five-year test is whether SCHOTT Pharma retains a meaningful place in the evolving injection architecture. Injectable biologics should remain a large category, but oral GLP-1 products, dual sourcing and integrated devices can redistribute the profit pool. SCHOTT needs the number and technical value of injectable containers to grow enough to fill its capacity at attractive pricing; it does not need injections to retain every patient.

Foundation control can help this process by allowing long-term investment through temporary underutilization. The same control can prevent shareholders from forcing a different capital-allocation policy if returns disappoint. A fair valuation must recognize both sides. The appropriate discount compensates for weak minority control, related-party dependence, limited takeover optionality and low effective float, not for being German or family influenced.

The company would become a better investment under three connected conditions: a lower entry price, evidence that DDS has returned to growth, and proof that fiscal 2026 capex converts into rising ROCE and free cash flow. A lower price alone would compensate for uncertainty but not repair the thesis. Better results at a much higher valuation would improve the company while reducing the stock’s prospective return.

The judgment should be overturned positively if DDS resumes mid-single-digit growth, group margin exceeds 29%, capex falls below 13% of revenue and free cash flow exceeds EUR 120 million without working-capital release. It should be overturned negatively if fiscal 2027 growth remains below 4%, DDS margin stays below 30%, ROCE falls below 17%, or another major customer revises orders after the July agreement.

Bull reasons:

• DCS constant-currency revenue grew 8.3% and EBITDA 17.2% in the first half of fiscal 2026 as ready-to-use cartridges, vials and specialty products gained share.
• HVS share increased from 33% in fiscal 2021 to 57% in fiscal 2025, while group EBITDA margin rose from 25.3% to 28.4%.
• Approximately EUR 1.14 billion of remaining contractual obligations and EUR 143 million of customer advances provide evidence that some expansion is supported by long-term demand.
• Preliminary fiscal Q3 growth of about 8% and the raised 5–6% full-year guide indicate that the original bridge-year forecast was partly a customer-timing issue.
• Net debt below half a turn of EBITDA gives the company financial capacity to complete current expansions without material equity dilution.

Bear reasons:

• DDS constant-currency revenue fell 5.4% and EBITDA fell 18.0% in the first half of fiscal 2026 despite continued high demand for GLP-1 glass syringes.
• ROCE declined from 24.5% in fiscal 2021 to 18.7% in fiscal 2025 as capital expenditure remained elevated.
• One customer accounted for more than 10% of first-half revenue and was important enough for its revised syringe schedule to affect full-year group guidance.
• Fiscal 2026 consensus free cash flow implies a yield below 2%, leaving little compensation if growth settles below management’s target.
• The 77% controller, controller-owned general partner and approximately 18% effective index free float restrict minority influence, takeover value and liquidity.

Pre-mortem script one: during fiscal 2027 the major glass-syringe customer again lowers its volume forecast as it qualifies a second supplier and shifts part of its obesity portfolio toward cartridges or oral formulations. Hungary operates below planned utilization, DDS revenue falls another 8%, and the segment margin declines from about 30% to 24%. Group EPS falls toward EUR 0.70. A market multiple of 16 times produces a price near EUR 11, approximately half the current quotation.

Pre-mortem script two: SCHOTT Pharma spends another EUR 300–350 million over fiscal 2027–2028 on sterile capacity, but industry packaging growth remains near 3–4%. DCS margin stalls at 24–25%, polymer assets require impairment, and group ROCE falls below 14%. Even if EPS remains around EUR 1.00, investors recategorize the company as a mature glass converter and apply 14–16 times earnings, resulting in a EUR 14–16 share price.

SCHOTT Pharma is a good regulated manufacturing franchise whose compounder credentials remain unproven at the cash-flow level. The July guidance increase materially improves the twelve-month outlook and lowers the probability that fiscal 2026 marks structural deterioration. The current price already reflects a meaningful recovery from the March low and sits close to the conservative value estimate.

Owning the shares at EUR 22.15 requires confidence that DDS growth resumes, capex moderates and the margin approaches 29–30%. The expected base-case annualized return of about 5% is modest relative to the operating, governance and liquidity risks. The business is worth monitoring and can be held within a diversified portfolio, but the current price does not offer the 20% margin of safety required for a fresh purchase.

【Company-profile scores】

• Fundamental quality: high
• Growth: medium
• Moat: medium
• Financial soundness: strong
• Management credibility: medium
• Valuation attractiveness: medium
• Risk level: medium
• Suitable investor type: long-term growth investors able to tolerate capital-intensive execution and controlled-company governance

【Investment rating】

• Rating: Hold
• One-line thesis: DCS and glass-syringe strength support recovery, but capital intensity, polymer underutilization and controlled KGaA governance limit prospective returns.
• Ideal buy price:

【Ideal Buy Price】16–18 EUR

Basis: at least 20% below the EUR 22.5 conservative value, with no deterioration in DDS contracts, balance-sheet strength or long-term margin potential.

• Acceptable hold price: EUR 22–30
• Clearly overvalued price: EUR 38–42
• Current-price classification: acceptable hold
• Whether to wait for a better price: yes. A purchase would require EUR 18 or less, continued group growth above 5%, no further major customer revision and evidence that DDS margin is stabilizing. Waiting risks missing a rapid re-rating if fiscal 2027 guidance returns immediately to 6–8% growth.
• Target holding horizon: 3–5 years
• Expected annualized return: conservative about 1%; base about 5%; optimistic about 12%, including modest dividends over four years.
• Max-loss risk: approximately 50%, toward EUR 11, if customer dual sourcing, oral substitution and underutilized capacity reduce DDS margin to the mid-twenties while the earnings multiple compresses.
• Reassessment-trigger signals: DDS constant-currency growth below -5% after fiscal 2026; DDS margin below 30% for two half-years; group ROCE below 17%; annual capex above EUR 170 million without higher contracted revenue; or another top-customer schedule revision.

【Valuation Range】

• current: 22.15 EUR (close as of 2026-08-05)
• bear (conservative · ideal buy zone): [16, 18]
• base (fair · acceptable hold zone): [22, 30]
• bull (optimistic · above the clearly-overvalued line): [38, 42]

Research uncertainties, sources and other tickers mentioned

The largest blind spot is product-level disclosure. SCHOTT Pharma does not report revenue, margin, capacity or utilization separately for glass and polymer syringes. The analysis can identify the direction and segment effect of the polymer decline but cannot calculate its precise residual earnings drag.

A second blind spot is GLP-1 exposure. Customers, molecules, revenue share, sole-source status and contract quantities are confidential. Management’s GLP-1 references establish exposure but do not permit a dependable revenue model.

A third is capacity economics. Site-level investment, output, qualification schedules, customer advances and expected returns are not reported together. The disclosed contract backlog supports demand visibility but cannot prove that each project will earn above the cost of capital.

A fourth is maintenance capex. The EUR 75–90 million estimate used in owner earnings is an analytical assumption anchored to depreciation and the installed asset base, not a company-disclosed figure.

A fifth is the incomplete fiscal third-quarter information. The July 8 figures are preliminary. Segment accounts, free cash flow, working capital and detailed management commentary will only become available with the August 12 nine-month release.

Principal sources include SCHOTT Pharma’s fiscal 2025 annual report and segment disclosures; the fiscal 2026 half-year report and presentation; the July 8, 2026 ad-hoc guidance announcement; the current IR factbook; the IPO and Deutsche Börse listing materials; official governance disclosures; Vara Research consensus; FDA container-closure and Drug Master File guidance; peer-company quarterly filings; and dated market-price and exchange-rate sources.

Other tickers mentioned:

• GXI.XETRA — Gerresheimer is the closest large European glass-packaging comparison and a warning about leverage, capacity ramps and execution.
• STVN.US — Stevanato Group is the closest premium pure-play peer in ready-to-use containment, syringes and integrated delivery systems.
• ATR.US — AptarGroup provides a diversified pharmaceutical dispensing and delivery-system valuation reference.
• WST.US — West Pharmaceutical Services is the premium container-closure and elastomer comparator with direct GLP-1 component exposure.
• LLY.US — Eli Lilly’s injectable and oral obesity portfolio illustrates both GLP-1 demand growth and modality-substitution risk.
• NVO.US — Novo Nordisk’s injectable and oral semaglutide products affect future syringe and cartridge demand architecture.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.